头颈癌同侧放疗中调强质子治疗与容积旋转调强放疗的急性毒性和患者报告结局比较
本研究比较2015至2020年接受同侧根治性放疗的扁桃体癌和涎腺癌患者采用调强质子治疗(IMPT)或容积旋转调强放疗(VMAT)的剂量学差异、患者报告结局(PRO)及医生报告的毒性。40例患者中,IMPT与多个危及器官剂量降低及疼痛、吞咽功能、口干、唾液黏稠、感觉改变、咳嗽、言语、不适感、社交进食等PRO恶化较少相关,医生报告的口腔疼痛也更少。
要点
- IMPT较VMAT降低多个危及器官剂量并减少多项患者报告结局的急性恶化。
- IMPT组医生报告的口腔疼痛少于VMAT组。
- 作者认为同侧头颈癌患者值得强烈考虑IMPT。
核心结论
- IMPT与危及器官剂量降低及多个头颈领域患者报告的急性恶化减少相关,作者认为同侧头颈癌患者值得强烈考虑IMPT。
研究设计与样本
- 分析放疗计划的剂量学差异,并比较2015至2020年接受同侧根治性放疗的扁桃体癌和涎腺癌患者采用VMAT或IMPT的患者报告结局及医生报告的毒性,共40例患者。
主要发现
- 在40例患者中,IMPT与多个危及器官剂量降低相关。
- IMPT与以下患者报告结局的恶化较少相关:疼痛、吞咽功能、口干、唾液黏稠、感觉改变、咳嗽、言语、不适感、社交进食。
- 医生报告的毒性显示IMPT组口腔疼痛较少。
临床怎么用
- 作者认为同侧头颈癌患者值得强烈考虑IMPT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intensity-modulated proton therapy (IMPT) demonstrates superior dose distribution over volumetric-modulated arc therapy (VMAT) for sparing organs-at-risk (OARs) in ipsilateral radiotherapy. To determine a clinical benefit, assessment of patient-reported outcomes (PRO) and physician-reported toxicities alongside a dosimetric analysis is needed. METHODS: Plans were analyzed for dosimetric differences. PROs were compared for patients undergoing ipsilateral curative-intent radiotherapy for tonsil and salivary gland cancers with VMAT or IMPT from 2015 to 2020. Physician-reported toxicities were compared. RESULTS: In 40 patients, IMPT was associated with decreased dose to multiple OARs and less deterioration in the following PROs: pain, swallowing function, dry mouth, sticky saliva, sensory change, cough, speech, feeling ill, and social eating. Physician-reported toxicities demonstrated less oral pain. CONCLUSION: IMPT is associated with decreased dose to OARs and less patient-reported acute deterioration in multiple head and neck domains. A strong consideration for IMPT in ipsilateral head and neck patients with cancer is warranted.
引用
- Jeans EB, Shiraishi S, Manzar G, et al. An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancers. Head Neck. 2021. PMID: 34859516. doi:10.1002/hed.26937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。